A Case Control Study of the Prevalence of Pulmonary Hypertension in Patients With Myeloproliferative Diseases.

Study Overview
=================
Brief Summary
-----------------
Pulmonary hypertension (PH) is defined as a group of diseases characterised by an elevated mean pulmonary artery pressure (Ppa) ≥25 mmHg at rest. Recently, chronic myeloproliferative diseases (CMPD) associated with pulmonary hypertension were included in the group 5 category, corresponding to PH for which the aetiology is unclear and/or multifactorial. CMPD include chronic myelogenous leukaemia, chronic neutrophilic leukaemia and chronic eosinophilic leukaemia (which primarily express a myeloid phenotype and polycythaemia vera), idiopathic myelofibrosis, and essential thrombocytosis in which erythroid or megakaryocytic hyperplasia predominates. The purpose of this research: Assess Prevalence of PH in patients with CMPD in Northern Israel Describe the demographics and clinical course in patients with CMPD who are diagnosed with PH.

Detailed Description
-----------------
study will include the following: sex age BMI ethnicity age diagnosed with Myeloproliferative disease clinical manifestations of the myeloproliferative disease JAK2 mutation known hematological complications

Official Title
-----------------
A Case Control Study of the Prevalence of Pulmonary Hypertension in Patients With Myeloproliferative Diseases, and Correlation Between Patients Epidemiologic and Clinical Status and the Development of Pulmonary Hypertension.

Conditions
-----------------
Myeloproliferative Disease, Pulmonary Hypertension

Intervention / Treatment
-----------------
* Other: myeloproliferative disease


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1) consenting patients diagnosed with a myeloproliferative disease Exclusion Criteria: 1) Refusal to have an echocardiogram or answer the St. George respiratory questionnaire

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| myeloproliferative disease<br>Patients with Myeloproliferative Diseases as specified under inclusion and exclusion criteria | Other: myeloproliferative disease<br>* Echocardiogram, demographic data, St George respiratory questioner<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pulmonary hypertension | all patients with myeloproliferative diseases in the study will be evaluated by an echocardiogram. Pulmonary hypertension will be considered when the average pulmonary arterial pressure is equal or above 25 mmHg. | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| St George Respiratory Questionnaire |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Myeloproliferative disease, Pulmonary Hypertension